Abstract: Cerebral palsy (CP), a common and serious complication for premature infants, seriously threatens the health of premature infants. More and more evidence have shown that antenatal application of magnesium sulfate for fetal neuroprotection can decrease the incidence of CP in preterm infants. Based on the latest clinical research evidence of magnesium sulfate for fetal neuroprotective effect, The Society of Obstetricians and Gynaecologists of Canada(SOGC) developed the clinical practice guideline in 2019. This guideline provide opinions and recommendations on the gestational age, time and dosage regimen of using magnesium sulfate, whether you need a repeat course of antenatal magnesium sulfate and neonatal resuscitation. This article interpreted the main points of the guideline so as to provide reference for Chinese medical staffs.

Key words: Magnesium sulphate, Preterm birth, Cerebral palsy, Death, Neuroprotection